Drug Profile
MEDI 1814
Alternative Names: Aß42 Antibody; MEDI-1814Latest Information Update: 17 Feb 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 17 Feb 2023 Phase-I clinical development in Alzheimer's disease is ongoing in USA (IV) (AstraZeneca pipeline, February 2023)
- 17 Feb 2023 Phase-I clinical development in Alzheimer's disease is ongoing in USA (SC) (AstraZeneca pipeline, February 2023)
- 28 Mar 2022 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (IV, Injection)